“…According to the previous literatures, main compounds of MO, honokiol and magnolol, improve liver dysfunction hepatic steatosis via AMPK-SREBP-1c pathway in HFD-induced mice. 7 Magnolol has been studied to upregulate AKT, AMPK, and PPARα expression and suppress SREBP-1c generation. 17 AMPK is a key factor in regulating lipid metabolism, and the AMPK pathway is associated with a fatty acid synthesis and cholesterol synthesis in the localized area.…”